Athanor Capital’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Athanor Capital’s Portfolio RARX Stock Details RARX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-224,786	Closed	-$10.8M	–	596
2020 Q1	$10.8M	Buy	224,786 +170,386	+313%	+$7.93M	0.7%	42
2019 Q4	$2.55M	Buy	54,400 +31,400	+137%	+$1.39M	0.12%	102
2019 Q3	$544K	Buy	23,000 +9,400	+69%	+$279K	0.04%	147
2019 Q2	$409K	Buy	+13,600	New	+$312K	0.05%	101
2018 Q2	–	Sell	-67,150	Closed	-$357K	–	82
2018 Q1	$357K	Buy	+67,150	New	+$480K	0.17%	61

Other funds holding RARX

Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Athanor Capital's RARX Position: Q2 2020 in Review

Athanor Capital sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q2 2020, closing a stake of 224,786 shares — an estimated $10.8M sold.

Athanor Capital first reported a position in RARX in Q1 2018 and held it in 5 quarters. The position peaked at $10.8M in Q1 2020. 1 fund tracked by Wall St. Rank holds RARX as of Q2 2020.

Athanor Capital reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
Athanor Capital sold 224,786 Ra Pharmaceuticals, Inc. Common Stock shares in Q2 2020, an estimated $10.8M.
Athanor Capital first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
Athanor Capital's Ra Pharmaceuticals, Inc. Common Stock position peaked at $10.8M in Q1 2020.
1 fund tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q2 2020.

Based on Athanor Capital's 13F filing for Q2 2020, filed 13 Aug 2020.